Additional file 1: of Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections Teresa Kauf Vimalanand Prabhu Goran Medic Rebekah Borse Benjamin Miller Jennifer Gaultney Shuvayu Sen Anirban Basu 10.6084/m9.figshare.c.3767567_D1.v1 https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Cost-effectiveness_of_ceftolozane_tazobactam_compared_with_piperacillin_tazobactam_as_empiric_therapy_based_on_the_in-vitro_surveillance_of_bacterial_isolates_in_the_United_States_for_the_treatment_of_complicated_urinary_tract_infecti/4954739 Details regarding PACTS and Premier data. This additional file provides readers with additional details regarding the Program to Assess Ceftolozane/Tazobactam Susceptibility (PACTS) dataset which was used to provide susceptibility inputs for the model and also regarding the Premier research database which was used to help define the pathogen distribution in cUTI. (DOCX 29 kb) 2017-04-28 05:00:00 Cost-benefit analysis Ceftolozane Piperacillin Tazobactam Urinary tract infections United States Drug resistance